BG103522A - Състави на "ов" слят протеин и методи за тяхното получаване - Google Patents

Състави на "ов" слят протеин и методи за тяхното получаване

Info

Publication number
BG103522A
BG103522A BG103522A BG10352299A BG103522A BG 103522 A BG103522 A BG 103522A BG 103522 A BG103522 A BG 103522A BG 10352299 A BG10352299 A BG 10352299A BG 103522 A BG103522 A BG 103522A
Authority
BG
Bulgaria
Prior art keywords
methods
compositions
type protein
protein syntheses
type
Prior art date
Application number
BG103522A
Other languages
English (en)
Other versions
BG64288B1 (bg
Inventor
Michael Mann
Randy HECHT
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of BG103522A publication Critical patent/BG103522A/bg
Publication of BG64288B1 publication Critical patent/BG64288B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)

Abstract

Изобретението се отнася до състави на протеини тип Fc-ОВ, до методи за тяхното получаване и до приложението им. Изобретението се отнася до протеин, получен чрез генетичен или химичен синтез, при който имуноглобулиновата част Fc, нейна производна илианалог, са присъединени чрез синтез към N-терминалната част на протеин ОВ, на негова производна илианалог.
BG103522A 1996-12-20 1999-06-23 'ъ''ави на ов 'ля' про'...ин и м...'оди за 'яхно'о пол"-аван... BG64288B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77097396A 1996-12-20 1996-12-20
PCT/US1997/023183 WO1998028427A1 (en) 1996-12-20 1997-12-11 Ob fusion protein compositions and methods

Publications (2)

Publication Number Publication Date
BG103522A true BG103522A (bg) 2000-03-31
BG64288B1 BG64288B1 (bg) 2004-08-31

Family

ID=25090296

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103522A BG64288B1 (bg) 1996-12-20 1999-06-23 'ъ''ави на ов 'ля' про'...ин и м...'оди за 'яхно'о пол"-аван...

Country Status (26)

Country Link
EP (2) EP0954588B1 (bg)
JP (2) JP4175668B2 (bg)
KR (1) KR100937550B1 (bg)
CN (1) CN1195858C (bg)
AR (2) AR009436A1 (bg)
AT (1) ATE351910T1 (bg)
AU (1) AU5606098A (bg)
BG (1) BG64288B1 (bg)
BR (1) BR9713755A (bg)
CA (1) CA2275183A1 (bg)
CZ (1) CZ298203B6 (bg)
DE (1) DE69737266T2 (bg)
DK (1) DK0954588T3 (bg)
EA (2) EA004790B1 (bg)
ES (1) ES2280083T3 (bg)
HK (1) HK1021388A1 (bg)
HU (1) HU227088B1 (bg)
IL (1) IL130396A (bg)
NO (2) NO324506B1 (bg)
NZ (1) NZ514145A (bg)
PL (1) PL194159B1 (bg)
PT (1) PT954588E (bg)
RS (1) RS49927B (bg)
SK (1) SK287578B6 (bg)
WO (1) WO1998028427A1 (bg)
ZA (1) ZA9711239B (bg)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358862A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
ES2183351T3 (es) * 1997-04-17 2003-03-16 Amgen Inc Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos.
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
CA2321026A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
MEP42108A (en) 1998-10-23 2011-02-10 Kiren Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2407086A1 (en) * 2000-04-21 2001-11-01 Amgen, Inc. Integrin/adhesion antagonists
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
CN100404673C (zh) 2001-02-19 2008-07-23 默克专利有限公司 鉴定t细胞表位的方法及制备具有降低的免疫原性的分子的用途
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
JP2002306163A (ja) * 2001-04-11 2002-10-22 Chemo Sero Therapeut Res Inst 大腸菌を宿主とする遺伝子組換えヒトトロンビンの調製方法
WO2003034996A2 (en) 2001-10-22 2003-05-01 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP3936673B2 (ja) * 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
EA011859B9 (ru) 2004-01-05 2013-07-30 Емд Лексиген Ресерч Сентер Корп. Соединения для адресной доставки препарата к ткани или органу-мишени
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2005077094A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
EP1773400A2 (en) 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
EP1773884B1 (en) 2004-08-03 2012-03-07 Innate Pharma Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor
EP1814590B2 (en) 2004-11-01 2013-12-11 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
CN101296942A (zh) * 2005-08-11 2008-10-29 安米林药品公司 具有可选择特性的杂合多肽
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
BRPI0617688A2 (pt) 2005-10-21 2011-06-07 Hoffmann La Roche método para expressão recombinante de um polipeptìdeo
AR059193A1 (es) 2006-01-31 2008-03-12 Bayer Schering Pharma Ag Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
CA2768965C (en) 2009-08-14 2019-06-04 George N. Pavlakis Use of il-15 to increase thymic output and to treat lymphopenia
WO2012050925A2 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Highly soluble leptins
WO2013009539A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
EP2764565B1 (en) 2011-10-05 2023-02-22 OneD Material, Inc. Silicon nanostructure active materials for lithium ion batteries and processes, compositions, components, and devices related thereto
RS58010B1 (sr) 2012-09-27 2019-02-28 Childrens Medical Ct Corp Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu
AU2014354831B2 (en) 2013-11-26 2017-10-26 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CA3036551A1 (en) 2016-09-12 2018-03-15 Aegerion Pharmaceuticals, Inc. Methods of detecting anti-leptin neutralizing antibodies
CN110183530A (zh) * 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CA2196200A1 (en) * 1994-07-29 1996-02-15 Michael Joseph Browne Novel compounds
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JPH0870875A (ja) * 1994-09-05 1996-03-19 Tosoh Corp 組換えアルカリフォスファタ−ゼ融合タンパク質
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
CA2358862A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
RU2178307C2 (ru) * 1995-12-27 2002-01-20 Джинентех Инк. Производные ов-протеина

Also Published As

Publication number Publication date
EA004790B1 (ru) 2004-08-26
CN1195858C (zh) 2005-04-06
AR009436A1 (es) 2000-04-12
SK287578B6 (sk) 2011-03-04
CN1246154A (zh) 2000-03-01
DK0954588T3 (da) 2007-05-14
EP0954588A1 (en) 1999-11-10
HUP0000302A3 (en) 2005-12-28
NO20071415L (no) 1999-08-19
RS49927B (sr) 2008-09-29
NZ514145A (en) 2003-08-29
ES2280083T3 (es) 2007-09-01
BG64288B1 (bg) 2004-08-31
EP0954588B1 (en) 2007-01-17
IL130396A (en) 2011-09-27
JP4659068B2 (ja) 2011-03-30
EP1835030A1 (en) 2007-09-19
WO1998028427A1 (en) 1998-07-02
HK1021388A1 (en) 2000-06-09
EA199900575A1 (ru) 2000-02-28
AU5606098A (en) 1998-07-17
EA200100216A1 (ru) 2001-08-27
NO324506B1 (no) 2007-11-05
JP4175668B2 (ja) 2008-11-05
YU27999A (sh) 2000-10-30
KR100937550B1 (ko) 2010-01-19
DE69737266T2 (de) 2007-11-08
KR20000069617A (ko) 2000-11-25
SK77499A3 (en) 2001-04-09
IL130396A0 (en) 2000-06-01
ZA9711239B (en) 1998-06-23
CZ9902036A3 (cs) 2000-10-11
PT954588E (pt) 2007-03-30
PL334242A1 (en) 2000-02-14
NO992779D0 (no) 1999-06-08
ATE351910T1 (de) 2007-02-15
DE69737266D1 (de) 2007-03-08
HUP0000302A2 (hu) 2000-06-28
HU227088B1 (en) 2010-06-28
BR9713755A (pt) 2000-02-01
PL194159B1 (pl) 2007-05-31
CZ298203B6 (cs) 2007-07-18
NO992779L (no) 1999-08-19
JP2001512417A (ja) 2001-08-21
AR059907A2 (es) 2008-05-07
EA004791B1 (ru) 2004-08-26
NO325096B1 (no) 2008-02-04
JP2008289487A (ja) 2008-12-04
CA2275183A1 (en) 1998-07-02

Similar Documents

Publication Publication Date Title
BG103522A (bg) Състави на "ов" слят протеин и методи за тяхното получаване
BG102983A (bg) Външномембранен протеин-106 полипептид от moraxella catarrhalis, негова генна последователност и приложения
WO1995030750A8 (fr) Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
EP1308461A3 (en) Antibodies to beta-amyloids or their derivatives and use thereof
ATE336511T1 (de) Peptide und peptidomimetika mit struktureller ähnlichkeit mit p53 und die die p53-funktion aktivieren
BG102071A (bg) Дребномолекулни инхибитори на ротамазна ензимна активност
IL130190A0 (en) Methods and compositions for polypeptide engineering
EP1088890A3 (en) Recombinant BPI proteins, uses of BPI proteins, and methods of preparing same
BG102950A (bg) АНТИТЕЛА ЗА ed-b ДОМЕН НА ФИБРОНЕКТИН, ТЕХНИЯТ СТРОЕЖ И ИЗПОЛЗУВАНИЯ
WO2000053758A3 (en) Compositions and methods for the treatment of immune related diseases
AU4815197A (en) Tetraphosphonate bicyclic trisanhydrides
CA2200423A1 (en) Novel estrogen receptor
BG103091A (bg) ИЗТЕГЛЯЩ РАЗТВОРИМ ТУМОРЕН НЕКРОЗИСЕН ФАКТОР С РЕЦЕПТОРИ ТИП-i И ТИП-ii
WO2000073452A3 (en) Compositions and methods for the treatment of immune related diseases
WO2000002916A3 (en) PEPTIDE COMPOSITIONS MIMICKING TGF-β ACTIVITY
BG102673A (bg) Смеси, добивани от зърна на еugеniа jамвоlаnа lамаrск, получаване и използване на посочените смеси и някои техни компоненти като лекарства
ATE394482T1 (de) Verfahren und zusammensetzungen für peptid-, protein- und peptidomimetische synthese
WO1999014241A3 (en) Compositions and methods for the treatment of immune related diseases
AU4011300A (en) Compositions and methods for the treatment of immune related diseases
DE69333952D1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
AU3711597A (en) A novel galanin receptor
DE69619808T2 (de) Chimäre msp und daf proteine mit einem telloberflächenlokalisierendem domän
AU5493298A (en) Stabilized pharmaceutical compositions and process for the preparation thereof
AU669149B2 (en) Expression signal-peptide-free staphylokinases
DE69734596D1 (de) "smoothened" proteine aus wirbeltieren